Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.54 |
| ▸ | MGAM | O43451 | 1/20 | 0.49 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SI | P14410 | 1/20 | 0.49 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | CNKSR1 | Q969H4 | 2/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3103837 | 1.00 | MAOB (0.54) | MAOBMGAMAMY1AGAASI | |
| SCHEMBL10973706 | 0.82 | MAOB (0.55) | MAOBMGAMAMY1AGAASI | |
| SCHEMBL7518420 | 0.81 | CA12 (0.44) | MAOBKDM4ECNKSR1AKT1CA12 | |
| SCHEMBL8477313 | 0.81 | CA12 (0.44) | MAOBKDM4ECNKSR1AKT1CA12 | |
| SCHEMBL5478840 | 0.80 | MAOB (0.61) | MAOBMGAMAMY1AGAASI | |
| SCHEMBL5478845 | 0.80 | MAOB (0.61) | MAOBMGAMAMY1AGAASI | |
| SCHEMBL3570478 | 0.79 | MAOB (0.60) | MAOBKDM4EDRD2DRD3ALDH1A1 | |
| SCHEMBL3570479 | 0.79 | MAOB (0.60) | MAOBKDM4EDRD2DRD3ALDH1A1 | |
| SCHEMBL162076 | 0.78 | KDM4E (0.77) | MAOBKDM4ECNKSR1CA1CA2 | |
| SCHEMBL162075 | 0.78 | KDM4E (0.77) | MAOBKDM4ECNKSR1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200385340-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | BIOTRON LTD (AU) | 2020-12-10 | — | — | US | disclosed |
| US-10683263-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2020-06-16 | — | — | US | disclosed |
| EP-2826770-B1 | ACYLGUANIDINE COMPOUNDS WITH ANTIVIRAL ACTIVITY | BIOTRON LTD (AU) | 2018-09-12 | — | — | EP | disclosed |
| US-20170362170-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | BIOTRON LTD (AU) | 2017-12-21 | — | — | US | disclosed |
| US-20160376231-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2016-12-29 | — | — | US | disclosed |
| EP-2659885-B1 | Hepatitis C Antiviral Compositions and Methods | BIOTRON LTD (AU) | 2016-11-09 | — | — | EP | disclosed |
| US-9440926-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2016-09-13 | — | — | US | disclosed |
| EP-2194976-B1 | Hepatitis C antiviral compositions comprising 5-(1-methylpyrazol-4-yl)2-naphthoylguanidine and 2'-C-methyladenosine or 2'-C-methylcytidine | BIOTRON LTD (AU) | 2015-12-09 | — | — | EP | disclosed |
| US-20150023921-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | BIOTRON LIMITED (AU) | 2015-01-22 | — | — | US | disclosed |
| EP-2826770-A1 | Acylguanidine compounds with antiviral activity | Biotron Limited (AU) | 2015-01-21 | — | — | EP | disclosed |
| EP-1902017-B1 | Antiviral acylguanidine compounds | BIOTRON LTD (AU) | 2014-03-26 | — | — | EP | disclosed |
| US-8669280-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2014-03-11 | — | — | US | disclosed |
| US-20140066487-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2014-03-06 | — | — | US | disclosed |
| EP-2659885-A1 | Hepatitis C Antiviral Compositions and Methods | Biotron Limited (AU) | 2013-11-06 | — | — | EP | disclosed |
| US-20100254942-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | BIOTRON LIMITED (AU) | 2010-10-07 | — | — | US | disclosed |
| EP-2194976-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | Biotron Limited (AU) | 2010-06-16 | — | — | EP | disclosed |
| US-20090099239-A1 | Antiviral Compounds and Methods | BIOTRON LIMITED (AU) | 2009-04-16 | — | — | US | disclosed |
| WO-2009018609-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | BIOTROM LIMITED (AU) | 2009-02-12 | — | — | WO | disclosed |
| EP-1902017-A1 | ANTIVIRAL COMPOUNDS AND METHODS | Biotron Limited (AU) | 2008-03-26 | — | — | EP | disclosed |
| WO-2006135978-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066487-A1 | ANTIVIRAL COMPOUNDS AND METHODS | MAVS, ZC3HAV1, EIF2AK2 | MAOB 1895/4885MGAM 3128/4885AMY1A 4441/4885 |
| US-20100254942-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | HAVCR2, HCCS, EIF2AK2 | MAOB 883/4885MGAM 1742/4885AMY1A 2281/4885 |
| US-20150023921-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | HAVCR2, HCCS, EIF2AK2 | MAOB 883/4885MGAM 1742/4885AMY1A 2281/4885 |
| US-10683263-B2 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | MAOB 1895/4885MGAM 3128/4885AMY1A 4441/4885 |
| US-20170362170-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | HAVCR2, HCCS, EIF2AK2 | MAOB 883/4885MGAM 1742/4885AMY1A 2281/4885 |
| US-20090099239-A1 | Antiviral Compounds and Methods | MAVS, ZC3HAV1, EIF2AK2 | MAOB 1895/4885MGAM 3128/4885AMY1A 4441/4885 |
| US-20160376231-A1 | ANTIVIRAL COMPOUNDS AND METHODS | MAVS, ZC3HAV1, EIF2AK2 | MAOB 1895/4885MGAM 3128/4885AMY1A 4441/4885 |
| US-20200385340-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | HAVCR2, HCCS, EIF2AK2 | MAOB 883/4885MGAM 1742/4885AMY1A 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.